These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

859 related articles for article (PubMed ID: 28558150)

  • 1. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
    Sharkey RM; McBride WJ; Cardillo TM; Govindan SV; Wang Y; Rossi EA; Chang CH; Goldenberg DM
    Clin Cancer Res; 2015 Nov; 21(22):5131-8. PubMed ID: 26106073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
    Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
    Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
    J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ; Schneider BJ; Ocean A; Johnson T; Gandhi L; Kalinsky K; Scheff R; Messersmith WA; Govindan SV; Maliakal PP; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2017 Oct; 23(19):5711-5719. PubMed ID: 28679770
    [No Abstract]   [Full Text] [Related]  

  • 11. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 12. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
    Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
    Seligson JM; Patron AM; Berger MJ; Harvey RD; Seligson ND
    Ann Pharmacother; 2021 Jul; 55(7):921-931. PubMed ID: 33070624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V; O'Shaughnessy J; Gray JE; Komiya T; Lang JM; Chang JC; Starodub A; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Wegener WA; Goswami T; Ocean AJ
    Ann Oncol; 2021 Jun; 32(6):746-756. PubMed ID: 33741442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
    Chang CH; Wang Y; Zalath M; Liu D; Cardillo TM; Goldenberg DM
    Mol Cancer Ther; 2016 Aug; 15(8):1910-9. PubMed ID: 27207776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?
    Zangardi ML; Spring LM; Nagayama A; Bardia A
    Expert Opin Investig Drugs; 2019 Feb; 28(2):107-112. PubMed ID: 30507322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
    Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
    Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors.
    Fenn KM; Kalinsky K
    Drugs Today (Barc); 2019 Sep; 55(9):575-585. PubMed ID: 31584574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.